OBJECTIVES: To determine the rate and clinicopathological features of @entity189 using immunostaining of transcription factor E3 and fluorescence in situ hybridization analysis. METHODS: We evaluated 638 @entity1 with @entity1358 treated at Sapporo Medical University Hospital, Sapporo, Japan, from 1990 to 2009 by reviewing all @entity1710 - @entity1711 -stained sections and carrying out immunostaining of transcription factor E3 for all cases. Fluorescence in situ hybridization analysis was carried out for @entity1 with positive immunostaining or with findings suspicious for @entity189 on @entity1710 - @entity1711 -stained sections. In this analysis, we set a cut-off level for split signals of at least 10% of nuclei. RESULTS: Of the 631 @entity1 , 20 (3.2%) were positive for immunostaining. Finally, five @entity1 were diagnosed with @entity189 (0.8%). Four of these @entity1 were female and aged less than 50 years, and three cases were diagnosed as stage IV with multiple regional lymph nodal or visceral metastases. The positive predictive value of immunostaining was 25%. CONCLUSION: @entity1 with @entity1358 tend to be younger, more frequently female and diagnosed at a more advanced stage. Immunostaining followed by fluorescence in situ hybridization analysis is an accurate and cost-effective approach for diagnosis of @entity1358 .

Clinicopathological characteristics of Xp11.2 XXXX in adolescents and adults: Diagnosis using immunostaining of transcription factor E3 and fluorescence in situ hybridization analysis.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1711 :: ('MESH:D004801', 'Chemical') :: ['eosin'] @entity189 :: ('MESH:D002277', 'Disease') :: ['Xp11.2 translocation carcinoma'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma', 'Xp11 translocation renal cell carcinoma'] @entity1710 :: ('MESH:D006416', 'Chemical') :: ['hematoxylin']
@entity1358 :: (MESH:D002292,Disease) :: ['translocation renal cell carcinoma']
